InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Senti Biosciences Holdings, Inc.

SNTI Clue Score14
United States Fiscal year ends December CIK 0001854270
$0.31 -2.27% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.31 −96.82% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 26 May 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2021Revenue2.3Operating income−40.4Net income−55.3EPS, diluted−19.00Fiscal year 2022Revenue3.3 +43.4%Operating income−62.1Net income−58.2EPS, diluted−2.23Fiscal year 2023Revenue2.0 −39.8%Operating income−92.7Net income−71.1EPS, diluted−16.01Fiscal year 2024Revenue0.0 −100.0%Operating income−61.0Net income−52.8EPS, diluted−12.03Fiscal year 2025Revenue0.0Operating income−68.8Net income−61.4EPS, diluted−2.73
FY2021FY2022FY2023FY2024FY2025
Revenue 2.3 3.3 2.0 0.0 0.0
Growth +43.4% −39.8% −100.0%
Operating income −40.4 −62.1 −92.7 −61.0 −68.8
Net income −55.3 −58.2 −71.1 −52.8 −61.4
Growth
EPS, diluted −19.00 −2.23 −16.01 −12.03 −2.73

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2021Operating margin−1,765.4%Net margin−2,414.6%Free cash flow margin−1,753.7%Fiscal year 2022Operating margin−1,889.3%Net margin−1,771.5%Free cash flow margin−2,321.1%Fiscal year 2023Operating margin−4,687.9%Net margin−3,592.4%Free cash flow margin−3,257.5%Fiscal year 2024Fiscal year 2025Operating margin−312,631.8%Net margin−279,263.6%Free cash flow margin−198,363.6%
FY2021FY2022FY2023FY2024FY2025
Operating margin −1,765.4% −1,889.3% −4,687.9% n/a −312,631.8%
Net margin −2,414.6% −1,771.5% −3,592.4% n/a −279,263.6%
Free cash flow margin −1,753.7% −2,321.1% −3,257.5% n/a −198,363.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−34.6Capital expenditure−5.5Free cash flow−40.2Fiscal year 2022Operating cash flow−34.9Capital expenditure−41.4Free cash flow−76.3Fiscal year 2023Operating cash flow−52.4Capital expenditure−12.0Free cash flow−64.4Fiscal year 2024Operating cash flow−41.4Capital expenditure−0.0Free cash flow−41.4Fiscal year 2025Operating cash flow−43.4Capital expenditure−0.2Free cash flow−43.6
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −34.6 −34.9 −52.4 −41.4 −43.4
Capital expenditure −5.5 −41.4 −12.0 −0.0 −0.2
Free cash flow −40.2 −76.3 −64.4 −41.4 −43.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash56.0Shareholders’ equity−111.5Fiscal year 2022Cash57.6Shareholders’ equity127.3Fiscal year 2023Cash35.9Shareholders’ equity66.9Fiscal year 2024Cash48.3Shareholders’ equity25.6Fiscal year 2025Cash16.4Shareholders’ equity5.6
FY2021FY2022FY2023FY2024FY2025
Cash 56.0 57.6 35.9 48.3 16.4
Shareholders’ equity −111.5 127.3 66.9 25.6 5.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−1,765.4% −1,889.3% −4,687.9% n/a −312,631.8%
−2,414.6% −1,771.5% −3,592.4% n/a −279,263.6%
−1,753.7% −2,321.1% −3,257.5% n/a −198,363.6%
Spending
958.4% 856.5% 1,625.4% n/a 170,845.5%
927.5% 1,163.3% 1,879.5% n/a 118,922.7%
241.9% 1,259.1% 608.6% n/a 890.9%
Returns
n/a −45.7% −106.2% −205.8% −1,099.3%
−57.2% −32.2% −59.5% −54.0% −119.9%
Balance and payout
37.6% 29.6% 44.0% 48.1% 89.1%